TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infar (Q74653973)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 June 1998

Language	Label	Description	Also known as
English	TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infar	scientific article published on 01 June 1998

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

unstable angina

1 reference

based on heuristic

inferred from title

myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

E M Antman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

0 references

publication date

1 June 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

135

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

6 Pt 3 Su

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S353-60

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Thrombin hypothesis of thrombus generation and vascular lesion formation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Activation of blood coagulation by plaque rupture: mechanisms and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Advances in antithrombotic drug therapy for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

2 references

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Enoxaparin for thromboembolism prophylaxis in spinal injury: preliminary report on experience with 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970265-0

7 January 2021

Identifiers

10.1016/S0002-8703(98)70265-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9628449%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74653973&oldid=1933534980"